A Randomized, Subject and Investigator-blinded, Placebo Controlled, Cross-over, Multi-center Proof of Concept (PoC) Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and PK of LML134 in Shift Work Disorder (SWD) Patients
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs LML 134 (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 27 Jul 2017 Planned End Date changed from 16 Dec 2017 to 14 Mar 2018.
- 27 Jul 2017 Planned primary completion date changed from 15 Dec 2017 to 13 Mar 2018.
- 22 Jul 2017 Status changed from not yet recruiting to recruiting.